Development of 5-Substituted N -Methylmorphinan-6-ones as Potent Opioid Analgesics with Improved Side-Effect Profile
International Journal of Medicinal Chemistry · 2012
DOI: 10.1155/2012/208039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Medicinal Chemistry, 2012. Verfasst von Helmut Schmidhammer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Austrian Science Fund FWF, Austrian Science Fund, European Community.
Abstract (Originalsprache)
One of the most important functions of the opioid system is the control of pain. Among the three main opioid receptor classes ( μ , δ , κ ), the μ (MOR) is the main type targeted for pharmacotherapy of pain. Opioid analgesics such as morphine, oxycodone and fentanyl are agonists at the MOR and are the mainstay for the treatment of moderate-to-severe pain. However, adverse effects related to opioid use are severe and often lead to early discontinuation and inadequate analgesia. The development of more effective and safer medications for the management of pain still remains a major direction in pharmaceutical research. Chemical approaches towards the identification of novel MOR analgesics with reduced side effects include structural modifications of 14-alkoxy- N -methylmorphinan-6-ones in key positions that are important for binding, selectivity, potency, and efficacy at opioid receptors. This paper describes a representative strategy to improve the therapeutic usefulness of opioid analgesics from the morphinan class of drugs by targeting position 5. The focus is on chemical and biological studies and structure-activity relationships of this series of ligands. We report on 14-alkoxymorphinan-6-ones having a methyl and benzyl group at position 5 as strong opioid antinociceptive agents with reduced propensity to cause undesired effects compared to morphine although interacting selectively with MORs.
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 52a, 6020 Innsbruck, Austria.
Förderung
- Austrian Science Fund FWF
- Austrian Science Fund
- European Community
- Drug Evaluation Committee of the College on Problems of Drug Dependence of the USA
Zitieren
APA
Schmidhammer, H., & Spetea, M. (2012). Development of 5-Substituted N -Methylmorphinan-6-ones as Potent Opioid Analgesics with Improved Side-Effect Profile. International Journal of Medicinal Chemistry. https://doi.org/10.1155/2012/208039
Vancouver
Schmidhammer H, Spetea M. Development of 5-Substituted N -Methylmorphinan-6-ones as Potent Opioid Analgesics with Improved Side-Effect Profile. International Journal of Medicinal Chemistry. 2012. doi:10.1155/2012/208039
BibTeX
@article{Schmidhammer2012,
author = {Schmidhammer, Helmut and Spetea, Mariana},
title = {Development of 5-Substituted N -Methylmorphinan-6-ones as Potent Opioid Analgesics with Improved Side-Effect Profile},
journal = {International Journal of Medicinal Chemistry},
year = {2012},
doi = {10.1155/2012/208039}
}
EUVIMED